AMNEAL PHARMACEUTICALS, INC. AMRX
19.77
(0.04)
(0.20%)
as of 25 Sep
- Market cap
- $6.3B
- P/E
- 39.5×
Follow AMRX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
34.62 | 31.87 | 54.78 | 500.50 |
+8 more quarters Free account |
P/S ratio |
1.77 | 1.29 | 1.31 | 1.07 | |
P/FCF ratio |
0.00 | 20.71 | 17.34 | 13.22 | |
P/Operating CF |
(260.09) | (146.89) | 30.30 | 26.55 | |
P/B ratio |
167.31 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.59 | 2.09 | 2.06 | 1.87 | |
EV/EBITDA |
12.12 | 9.60 | 9.70 | 8.79 | |
EV/Operating CF |
40.14 | 20.77 | 18.26 | 16.73 | |
EV/FCF |
(695.25) | 33.50 | 27.27 | 23.05 | |
Quick Ratio |
1.31 | 1.45 | 1.37 | 1.30 | |
Current Ratio |
2.20 | 2.47 | 2.17 | 2.13 | |
Net Debt/EBITDA |
13.95 | 12.84 | 13.71 | 18.06 | |
Debt/Assets |
70.71% | 74.19% | 69.92% | 71.49% | |
Debt/Equity |
80.86 | (57.14) | (36.06) | (23.41) | |
Asset Turnover |
0.87 | 0.88 | 0.84 | 0.83 | |
Operating CF/Net income |
(0.37) | (0.43) | 3.72 | 50.00 | |
Capex/Depreciation |
(2.37) | (0.46) | (0.86) | (0.38) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.90% | 5.31% | 4.28% | 8.08% | |
Selling, General and Administrative Expense of Revenue |
18.68% | 19.22% | 17.99% | 17.57% | |
Intangible Assets out of Total Assets |
0.31 | 0.32 | 0.32 | 0.33 | |
Share Based Compensation of Revenue |
1.31% | 1.22% | 1.01% | 1.05% | |
Graham Net Nets |
(0.33) | (0.46) | (0.47) | (0.60) | |
Graham Number |
1.08 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
2.89% | 3.14% | 1.83% | 0.20% | |
Free Cash Flow Yield |
(0.21%) | 4.83% | 5.77% | 7.56% | |
Revenue per Share |
2.49 | 2.29 | 2.60 | 2.50 | |
Operating CF per Share |
(0.07) | (0.08) | 0.42 | 0.38 | |
Capex per Share |
(0.38) | (0.07) | (0.15) | (0.07) | |
Free Cash Flow per Share |
(0.45) | (0.15) | 0.27 | 0.31 | |
Cash per Share |
0.43 | 0.64 | 0.99 | 0.75 | |
Shareholders Equity per Share |
0.10 | (0.15) | (0.23) | (0.35) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.10 | (0.15) | (0.23) | (0.35) | |
Free Cash Flow |
(143.99) | (48.45) | 84.86 | 95.99 | |
Working Capital |
1,063.84 | 1,069.86 | 1,029.55 | 976.37 | |
Capital Expenditures |
(122.74) | (21.71) | (45.45) | (22.46) | |
Net Current Asset Value |
(1,796.29) | (1,788.28) | (1,838.43) | (1,871.35) | |
EV/EBIT |
17.76 | 14.59 | 15.76 | 15.32 | |
Capex to Sales |
0.15 | 0.03 | 0.06 | 0.03 | |
Net Profit Margin |
7.24% | 8.62% | 4.31% | 0.30% | |
Price to Operating Income |
12.17 | 9.02 | 10.02 | 8.79 | |
| Other line items | |||||
Average Receivables |
915.01 | 803.05 | 835.91 | 821.56 | |
Average Payables |
694.01 | 645.77 | 748.38 | 701.46 | |
Average Inventory |
643.46 | 621.53 | 609.38 | 605.43 | |
Average Assets |
3,599.57 | 3,452.73 | 3,589.86 | 3,530.43 | |
Average Common Equity |
(39.75) | (88.98) | (90.42) | (101.76) |
Columns are period end dates